DOL Finalizes Sweeping Pharmacy Benefit Manager Disclosure Rule
New federal mandate forces PBMs to disclose compensation data to self-funded employers by 2027.
1New Federal Disclosure Mandate
The U.S. Department of Labor finalized a rule requiring pharmacy benefit managers to disclose comprehensive compensation data to self-insured employer clients. Starting in July 2027, PBMs must report payments received from drugmakers and pharmacies. Regulators estimate this transparency initiative will reduce total drug costs for employers and workers by $22 billion over a decade.
2Scope of Required Disclosures
PBMs must now reveal negotiated rebates and spread payments, which occur when plans pay more for drugs than pharmacies are reimbursed. These disclosures are mandatory during contract negotiations and renewals, with updates required every six months. Employers gain the right to audit these disclosures annually to ensure compliance and verify the accuracy of financial reporting.
3Market Context and Criticism
The Big Three PBMs—Express Scripts, Caremark, and Optum Rx—control approximately 80% of U.S. prescriptions. Critics argue these entities leverage market dominance to maintain opaque fee structures. Recent data indicates that drug costs are projected to rise by 11.5% in 2026, intensifying pressure on employers to demand greater visibility into their pharmaceutical spending.
4Enforcement and Compliance Risks
The DOL rule introduces severe consequences for non-compliance, including significant financial penalties and the potential invalidation of existing contracts. The department estimates that PBMs will incur $1 million in initial compliance costs during the first year, followed by $300,000 in annual recurring expenses to maintain the required reporting systems and audit readiness.
5Industry Opposition and Lobbying
The Pharmaceutical Care Management Association, the primary PBM lobby, vociferously opposes the rule, labeling it government overreach. Industry groups argue that the regulation is redundant due to the Consolidated Appropriations Act of 2026. They contend that forcing these disclosures will disproportionately burden mid-sized PBMs, potentially driving smaller competitors out of the market entirely.
6Regulatory Alignment Strategy
The DOL acknowledged potential overlap with the Consolidated Appropriations Act but maintained that the two regimes are complementary. While the CAA focuses on retrospective reporting of drug utilization, the new DOL rule mandates upfront disclosures. This distinction aims to empower employers to compare PBM offerings effectively before finalizing contracts, enhancing overall market competition.
7Employer Perspective and Accountability
Employer groups, including the ERISA Industry Committee, support the rule as a tool for vendor accountability. Many large employers currently report insufficient insight into how their health plans are managed. By accessing granular data on rebates and fees, these organizations aim to ask harder questions and hold their PBM partners to stricter performance standards.
8Long-term Market Implications
While transparency is not a total solution for rising drug costs, experts suggest it will encourage more aggressive competition among PBMs. By shifting power toward employers, the rule aims to dismantle the hidden fee structures that have historically shielded middlemen. The success of this policy depends on how effectively employers utilize this newfound data.
Original article: HR Dive — DOL Finalizes Sweeping Pharmacy Benefit Manager Disclosure Rule